Syros Pharmaceuticals (NASDAQ:SYRS) Upgraded to Hold by Zacks Investment Research
According to Zacks, “Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company’s product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
A number of other brokerages also recently weighed in on SYRS. Wedbush reiterated an outperform rating and issued a $13.00 target price on shares of Syros Pharmaceuticals in a report on Thursday, April 25th. Roth Capital started coverage on Syros Pharmaceuticals in a report on Friday, July 12th. They issued a buy rating and a $17.00 target price for the company. HC Wainwright reiterated a neutral rating on shares of Syros Pharmaceuticals in a report on Thursday, May 2nd. BidaskClub upgraded Syros Pharmaceuticals from a hold rating to a buy rating in a report on Friday, July 12th. Finally, ValuEngine upgraded Syros Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, June 26th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Buy and a consensus price target of $16.03.
Syros Pharmaceuticals (NASDAQ:SYRS) last issued its earnings results on Thursday, August 1st. The company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.06). The business had revenue of $0.46 million during the quarter, compared to the consensus estimate of $0.42 million. Syros Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 3,137.55%. As a group, analysts predict that Syros Pharmaceuticals will post -1.94 EPS for the current year.
In other news, major shareholder Venture Fund Vii L.P. Arch sold 63,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $7.77, for a total transaction of $489,510.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 14.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of Montreal Can increased its holdings in shares of Syros Pharmaceuticals by 11,319.2% during the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock valued at $27,000 after acquiring an additional 2,943 shares in the last quarter. BNP Paribas Arbitrage SA bought a new stake in shares of Syros Pharmaceuticals during the first quarter valued at approximately $48,000. Bank of America Corp DE increased its holdings in shares of Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock valued at $98,000 after acquiring an additional 11,711 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. increased its holdings in shares of Syros Pharmaceuticals by 8.3% during the first quarter. Los Angeles Capital Management & Equity Research Inc. now owns 40,380 shares of the company’s stock valued at $369,000 after acquiring an additional 3,100 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of Syros Pharmaceuticals by 4.5% during the first quarter. Alps Advisors Inc. now owns 81,287 shares of the company’s stock valued at $743,000 after acquiring an additional 3,519 shares in the last quarter. Hedge funds and other institutional investors own 63.72% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Featured Article: Diversification For Individual Investors
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.